Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus MYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus MYCHEL.
FORBAXIN vs MYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
IV: 500 mg every 12 hours, infused over 30 minutes.
Adults: 200 mg orally twice daily for 14 days.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Renal (60-70% unchanged), biliary/fecal (20-30%)
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Category C
Category C
Antibiotic
Antibiotic